TITLE

Bone Disorders in Human Immunodeficiency Virus Infection

AUTHOR(S)
Glesby, Marshall J.
PUB. DATE
September 2003
SOURCE
Clinical Infectious Diseases;9/1/2003 Supplement 2, Vol. 37, pS91
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Osteopenia, osteoporosis, and osteonecrosis are the most significant bone disorders affecting patients with human immunodeficiency virus (HIV) infection. HIV-infected patients receiving potent antiretroviral therapy have a high prevalence of reduced bone mineral density (BMD). However, patients not receiving antiretrovirals also have a higher than expected prevalence of reduced BMD, which suggests that HIV itself may be a contributing factor, mediated by immune activation and cytokines. The risk of fractures remains undefined in this population, and no data exist on interventions to increase BMD and prevent fractures. Osteonecrosis has been reported in HIV-infected patients since 1990, and its incidence appears to be increasing. Available data suggest that corticosteroid use and other risk factors contribute significantly to its pathogenesis.Controlled studies have not supported the contention that protease inhibitors increase the risk of osteonecrosis. An improved understanding of the pathogenesis of these bone disorders should result in better preventative and therapeutic measures.
ACCESSION #
10854778

 

Related Articles

  • Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. Gazzola, Lidia; Bellistri, Giusi Maria; Tincati, Camilla; Ierardi, Valentina; Savoldi, Alessia; del Dole, Angelo; Tagliabue, Luca; Marchetti, Antonella d'Arminio Monforte1 and Giulia // Journal of Translational Medicine;2013, Vol. 11 Issue 1, p1 

    Background: HIV-infected patients display an increased and early incidence of osteopenia/osteoporosis. We investigated whether bone metabolism disorders in HIV-infected patients are related to immune hyperactivation and premature immune senescence. Methods: Bone mineral density (BMD) was...

  • Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. Negredo, Eugenia; Bonjoch, Anna; Gómez-Mateu, Moisés; Estany, Carla; Puig, Jordi; Perez-Alvarez, Nuria; Rosales, Joaquin; di Gregorio, Silvana; Rio, Luis del; Gómez, Guadalupe; Clotet, Bonaventura // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: Algorithms for bone mineral density (BMD) management in HIV-infected patients are lacking. Our objective was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of progression to osteopenia/osteoporosis. Methods: All DXA scans...

  • Increased prevalence, progression to osteoporosis observed in patients with HIV.  // Infectious Disease News;Dec2010, Vol. 23 Issue 12, p29 

    The article reports on a study which revealed an increased prevalence and progression to osteoporosis in patients with HIV.

  • Managing the adverse effects of bisphosphonate therapy on the jaw. Rizzolo, Denise; Sedrak, Mona // JAAPA: Journal of the American Academy of Physician Assistants (;Nov2009, Vol. 22 Issue 11, p48 

    The article focuses on the effects of treating bone loss from osteoporosis and osteopenia therapy using bisphosphonates. It states that patients taking bisphosphonates developed a bisphosphonate-related osteonecrosis of the jaws (BRONJ). It notes that BRONJ patients must undergo a comprehensive...

  • Abnormalities in the bone mineral metabolism in HIV-infected patients. García Aparicio, A.; Muñoz Fernández, S.; González, J.; Arribas, J.; Peña, J.; Vázquez, J.; Martínez, M.; Coya, J.; Martín Mola, E. // Clinical Rheumatology;Aug2006, Vol. 25 Issue 4, p537 

    Objective: To evaluate bone mineral metabolism in HIV infected and asymptomatic patients receiving highly active antiretroviral therapy (HAART) containing protease inhibitors (PI) and naïve patients. Methods: We studied 30 asymptomatic HIV infected male patients, 13 in the naive group and 17...

  • Antiretrovirals.  // Reactions Weekly;4/24/2004, Issue 998, p9 

    Discusses research being done on avascular necrosis in HIV-infected patients receiving antiretroviral treatment. Reference to a study by M. E. Valencia and colleagues, published in the March 2003 issue of "HIV Clinical Trials" journal; Risk factors for osteonecrosis; Components of the...

  • Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review. Yombi, Jean-Cyr; Vandercam, Bernard; Wilmes, Dunja; Dubuc, Jean-Emile; Vincent, Anne; Docquier, Pierre-Louis // Clinical Rheumatology;Jul2009, Vol. 28 Issue 7, p815 

    Osteonecrosis of the femoral head (ONFH) typically affects relatively young, active patients and frequently follows an unrelenting course resulting in considerable loss of function. In human immunodeficiency virus-infected patients, ONFH is a growing problem. Etiology, pathogenesis, and...

  • Aseptic Necrosis in HIV Seropositive Patients: A Possible Etiologic Role for Megestrol Acetate. Koller, Elizabeth; Mann, Marianne; Malozowski, Saul; Bacsanyi, Janos; Gibert, Cynthia // AIDS Patient Care & STDs;Aug2000, Vol. 14 Issue 8, p405 

    The association between pharmacologic doses of corticosteroids and the development of aseptic bone necrosis has been well documented. Recent reports have described the corticosteroid activity of megestrol acetate. A retrospective review of adverse events reported to the U.S. Food and Drug...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Jan2001, Vol. 15 Issue 1, p53 

    Presents news updates on antiviral agents for HIV infections as of January 2001. Incidence of osteonecrosis of the hip among HIV patients; Potential complications of antiretroviral therapy for treating HIV infections; Commercial release of the antiretroviral agent didanosine by Bristol-Myers...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics